Adrenal function recovery after durable OCS-sparing with benralizumab in the PONENTE study

Andrew Menzies-Gow* (Corresponding Author), Mark Gurnell, Liam G Heaney, Jonathan Corren, Elisabeth H Bel, Jorge Maspero, Timothy Harrison, David J Jackson, David Price, Njira Lugogo, James Kreindler, Annie Burden, Alex de Giorgio-Miller, Sarai Faison, Kelly Padilla, Ubaldo J Martin, Esther Garcia Gil, PONENTE Study Group

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Oral corticosteroid dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's oral corticosteroid-reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a final dosage ≤5 mg·day-1 (median, 0.0 mg [range, 0.0-40.0]).The maintenance phase assessed the durability of corticosteroid reduction and further adrenal function recovery. For approximately 6 months, patients continued benralizumab 30 mg every 8 weeks without corticosteroids or with the final dosage achieved during the reduction phase. Investigators could prescribe corticosteroids for asthma exacerbations or increase daily dosages for asthma control deteriorations.Outcomes included changes in daily oral corticosteroid dosage, Asthma Control Questionnaire 6 (ACQ-6), and St. George's Respiratory Questionnaire (SGRQ), as well as adrenal status, asthma exacerbations, and adverse events.598 patients entered PONENTE; 563 (94.1%) completed the reduction phase and entered the maintenance phase. From the end of reduction to the end of maintenance, the median oral corticosteroid dosage was unchanged (0.0 mg; [range, 0.0-40.0]), 3.2% (n=18/563) of patients experienced daily dosage increases, the mean ACQ-6 score decreased from 1.26 to 1.18, and 84.5% (n=476/563) of patients were exacerbation free. The mean SGRQ improvement (-19.65 points) from baseline to the end of maintenance indicated substantial quality-of-life improvements. Of patients entering the maintenance phase with adrenal insufficiency, 32.4% (n=104/321) demonstrated an improvement in adrenal function. Adverse events were consistent with previous reports.Most patients successfully maintained maximal oral corticosteroid reduction whilst achieving improved asthma control with few exacerbations and maintaining or recovering adrenal function.

Original languageEnglish
Article number2103226
Number of pages13
JournalEuropean Respiratory Journal
Issue number6
Early online date1 Dec 2022
Publication statusPublished - 1 Dec 2022


  • Ashtma
  • asthma control
  • corticosteroids
  • health-related quality of life


Dive into the research topics of 'Adrenal function recovery after durable OCS-sparing with benralizumab in the PONENTE study'. Together they form a unique fingerprint.

Cite this